US FDA grants clearance for the use of Verdeca’s HB4 stress-tolerant soybeans in human food

8cbd8b5a-716e-45e1-8dc2-75e602e028c8articleimage.jpg

11 Aug 2017 --- Arcadia Biosciences Inc. and Bioceres S.A. have announced that the US Food and Drug Administration (FDA) has completed its full review of the safety evaluation for HB4 soybeans, produced by their joint venture, Verdeca. The FDA’s notice to Verdeca allows products derived from HB4 soybeans to be used commercially in human food and animal feed. 

The US FDA uses its Biotechnology Notice process to review and assess safety data provided by companies developing new plant varieties using advanced breeding technologies. The data provided to the FDA is consistent with international regulatory requirements for genetically modified crops and will be used by Verdeca and its global partners for future regulatory submissions, the companies report.

Verdeca’s HB4 soybeans have undergone extensive testing, including multi-location field trials in Argentina and the US and multiple regulatory field trials. The results of these trials demonstrate that the HB4 trait can provide yield advantages under stress conditions – including drought and low-water conditions – found in several soybean production areas.

“The HB4 gene holds great promise for bringing better yield stability to agriculture in areas that experience chronic water stress problems,” says Raj Ketkar, President and CEO of Arcadia Biosciences. “Our combined efforts aim to create significant value for soybean growers by increasing the productivity and sustainability of this important protein crop in the face of global climate challenges.”

“The FDA is one of the most prestigious regulatory agencies in the world, and its opinions are of reference to regulators everywhere,” says Federico Trucco, CEO of Bioceres. “In a way, this FDA clearance testifies to the quality standards implemented in HB4 product development and safety evaluations. We hope this decision will help expedite international regulatory clearances for HB4 soybeans, and bring us closer to the much-anticipated launch of this unique technology.”

Completion of the FDA’s review is another key regulatory achievement in the approval process for Verdeca’s HB4 drought stress tolerance trait. The trait has already been approved in Argentina by the Ministry of Agriculture, Livestock and Fisheries.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Avoid the snacks? To manage weight, timing of protein supplements matters

25 May 2018 --- Protein supplementation is finding its way into an ever-increasing range of formats, with on-the-go snacks and “bite-size” in particular seeing tremendous growth. However, new research by nutrition experts at Purdue University has shown that people looking to manage their weight with strength-training and protein supplements should consume their supplementation during a meal. 

Nutrition & Health News

US FDA takes action against OTC benzocaine products for teething infants

24 May 2018 --- The US Food and Drug Administration (FDA) has warned that over-the-counter (OTC) teething products containing benzocaine may pose a serious risk to infants and children. The popular numbing agent can offer temporary relief to sore gums in teething infants; however, the FDA advises that companies stop marketing and selling these products for use. The agency is also raising awareness of the risks that, they state, come with other oral health benzocaine products. 

Nutrition & Health News

US safety watchdog to US FDA: “Add warning labels to ginkgo biloba supplements”

16 May 2018 --- The Center for Science in the Public Interest (CSPI) is urging consumers to avoid supplements made with ginkgo biloba, which they claim can be adulterated. They propose that the supplement is ineffective in improving memory and circulation. The agency has compiled a letter to the FDA’s Office of Dietary Supplement Programs requesting warning labels on ginkgo packages.

Nutrition & Health News

“Key milestone”: Chr. Hansen trial finds probiotic potential for painkiller gut damage defense

16 May 2018 --- A Chr. Hansen clinical trial has demonstrated the effectiveness of probiotic strains in protecting against potential gut damage caused by the regular use of household painkillers. Chr. Hansen state that they will now focus on fully exploiting the strains full potential, deepening understanding of the underlying mechanisms and gathering sufficient data to publish in a scientific journal. The findings add to a growing research area using probiotics for health.

Nutrition & Health News

US Nutrition Facts labels: Deadline extension prompts “call for action” comments 

07 May 2018 --- The US Food and Drug Administration (FDA) has extended the compliance date for updating Nutrition Fact labels by 1.5 years. The move has prompted calls from lobby groups, including the Center for Science in the Public Interest (CSPI), who state that this should be a call to action for food manufacturers to update their labels before the deadline.

More Articles
URL : http://www.nutritioninsight.com:80/news/us-fda-grants-clearance-for-the-use-of-verdecas-hb4-stress-tolerant-soybeans-in-human-food.html